Stock Research for GTXI


Featured Broker: Ally Invest

Get the due diligence for another stock.


GTXI Stock Chart & Research Data

The GTXI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GTXI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GTXI Due diligence Resources & Stock Charts

The GTXI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GTXI Detailed Price Forecast - CNN Money CNN View GTXI Detailed Summary - Google Finance
Yahoo View GTXI Detailed Summary - Yahoo! Finance Zacks View GTXI Stock Research & Analysis -

Stock Analysis

TradeIdeas View GTXI Trends & Analysis - Trade-Ideas Barrons View GTXI Major Holders - Barrons
NASDAQ View GTXI Call Transcripts - NASDAQ Seeking View GTXI Breaking News & Analysis - Seeking Alpha
Spotlight View GTXI Annual Report - OTC Report View GTXI OTC Short Report -
TradeKing View GTXI Fundamentals - TradeKing Charts View GTXI SEC Filings - Bar Chart
WSJ View Historical Prices for GTXI - The WSJ Morningstar View Performance/Total Return for GTXI - Morningstar
MarketWatch View the Analyst Estimates for GTXI - MarketWatch CNBC View the Earnings History for GTXI - CNBC
StockMarketWatch View the GTXI Earnings - StockMarketWatch MacroAxis View GTXI Buy or Sell Recommendations - MacroAxis
Bullish View the GTXI Bullish Patterns - American Bulls Short Pains View GTXI Short Pain Metrics -

Social Media Mentions

StockTwits View GTXI Stock Mentions - StockTwits PennyStocks View GTXI Stock Mentions - PennyStockTweets
Twitter View GTXI Stock Mentions - Twitter Invest Hub View GTXI Investment Forum News - Investor Hub
Yahoo View GTXI Stock Mentions - Yahoo! Message Board Seeking Alpha View GTXI Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GTXI - Insider Cow View Insider Transactions for GTXI - Insider Cow
CNBC View GTXI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GTXI - OTC Markets
Yahoo View Insider Transactions for GTXI - Yahoo! Finance NASDAQ View Institutional Holdings for GTXI - NASDAQ

Stock Charts

FinViz View GTXI Stock Insight & Charts - StockCharts View GTXI Investment Charts -
BarChart View GTXI Stock Overview & Charts - BarChart Trading View View GTXI User Generated Charts - Trading View

Latest Financial News for GTXI

Why GTx, Tilray, and United Natural Foods Slumped Today
Posted on Friday September 21, 2018

Sometimes, what goes up must come down.

Here's Why GTx, Inc. Dropped Over 92% Today
Posted on Friday September 21, 2018

The company's only drug candidate failed a mid-stage clinical trial. The next clinic-ready assets are on the way -- in late 2019 or early 2020.

Pot-Enthusiasts Beware: GTx Shows How a Hot Trend Can Reverse
Posted on Friday September 21, 2018

Here’s a warning to all of those trading pot stocks at biotech-like valuations: The fall is swifter than the rise.

GTx Inc. stock drops 94% premarket after phase 2 trial failure
Posted on Friday September 21, 2018

GTx Inc. stock dropped as much as 94% in Friday premarket trade after the company said that enobosarm, its therapy intended for post-menopausal women with stress urinary incontinence, did not meet the primary endpoint in a phase 2 clinical trial. The double-blind and placebo-controlled trial had enrolled nearly 500 women. Enobosarm is the company's main product candidate, which it has been developing in stress urinary incontinence as well as breast cancer. GTx is also developing a preclinical candidate for prostate cancer. Company shares have surged nearly 26% to $23.29 over the last three months, compared with a 6.6% rise in the S&P 500 and a nearly 9% rise in the Dow Jones Industrial Average .

Stock Market & Investing Books

Enter a stock symbol to view the stock details.